Literature DB >> 20445429

Compulsive behaviors in patients with Parkinson's disease.

Gülay Kenangil1, Sibel Ozekmekçi, Melis Sohtaoglu, Ethem Erginöz.   

Abstract

OBJECTIVE: Several impulse control disorders (ICDs) may develop in patients with Parkinson's disease (PD). We aimed to identify the frequency and phenomenology of ICDs in our PD population.
METHODS: Among 554 PD patients examined in a 3-year period, we identified 33 patients with ICDs. Disease duration, gender, and age-matched 65 PD patients without ICDs were selected as controls. We noted age-at-onset, duration, and severity of PD, dose and types of dopaminergic treatment, as well as presence of motor complications in both groups.
RESULTS: Of 554 patients, 33 (5.9%) had ICDs, of whom, 27 were men (81%), mean age-at onset of PD was 48 and disease duration 8 years. While all patients with ICDs were on dopamine agonist drugs (+/- an adjuvant), all but 2 of controls were on dopamine agonists. Punding was the most frequent behavioral problem (57%), 42% exhibited aggressive hypersexuality, 27% compulsive eating, 24% pathologic shopping, and 21% compulsive medication. Severity of PD, presence of l-Dopa-induced motor complications, l-Dopa equivalent doses of dopamine agonists administered were not statistically different between 2 groups.
CONCLUSIONS: In this study performed in a tertiary clinic for movement disorders in Turkey, several ICDs occurred in a small group of PD patients, mostly in men with young-onset disease, similar to the previous reported series. However, in contrast to the Western series, the number of gamblers was quite low because gambling is illegal in our country. We did not find any association between ICDs and severity of PD as well as doses of dopaminergic agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20445429     DOI: 10.1097/NRL.0b013e31819f952b

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  8 in total

1.  Impulse control disorders in Parkinson's disease: clinical characteristics and implications.

Authors:  Robert F Leeman; Marc N Potenza
Journal:  Neuropsychiatry (London)       Date:  2011-04

2.  Impulse control disorders in Parkinson's disease: background and update on prevention and management.

Authors:  Robert F Leeman; Benjamin E Billingsley; Marc N Potenza
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

Review 3.  Does the Country Make a Difference in Impulse Control Disorders? A Systematic Review.

Authors:  Paloma Parra-Díaz; Juan Luis Chico-García; Álvaro Beltrán-Corbellini; Fernando Rodríguez-Jorge; Clara Lastras Fernández-Escandón; Araceli Alonso-Cánovas; Juan Carlos Martínez-Castrillo
Journal:  Mov Disord Clin Pract       Date:  2020-12-21

4.  Demographic and Clinical Predictors of Trait Impulsivity in Parkinson's Disease Patients.

Authors:  Maddeson Riley; Megan Bakeberg; Michelle Byrnes; Alexa Jefferson; Soumya Ghosh; Rick Stell; Frank L Mastaglia; Dana Hince; Ryan S Anderton
Journal:  Parkinsons Dis       Date:  2018-04-19

Review 5.  Medications, Deep Brain Stimulation, and Other Factors Influencing Impulse Control Disorders in Parkinson's Disease.

Authors:  Robert S Eisinger; Adolfo Ramirez-Zamora; Samuel Carbunaru; Brandon Ptak; Zhongxing Peng-Chen; Michael S Okun; Aysegul Gunduz
Journal:  Front Neurol       Date:  2019-02-26       Impact factor: 4.003

Review 6.  Ethnic Variation in the Manifestation of Parkinson's Disease: A Narrative Review.

Authors:  Aaron Ben-Joseph; Charles R Marshall; Andrew J Lees; Alastair J Noyce
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

Review 7.  Mechanisms of body weight fluctuations in Parkinson's disease.

Authors:  Andrea Kistner; Eugénie Lhommée; Paul Krack
Journal:  Front Neurol       Date:  2014-06-02       Impact factor: 4.003

Review 8.  Dopamine Agonists and Impulse Control Disorders: A Complex Association.

Authors:  Marie Grall-Bronnec; Caroline Victorri-Vigneau; Yann Donnio; Juliette Leboucher; Morgane Rousselet; Elsa Thiabaud; Nicolas Zreika; Pascal Derkinderen; Gaëlle Challet-Bouju
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.